Idelalisib

The drug produced by Lucius Pharmaceuticals, as an oral targeted therapy, exhibits significant clinical efficacy in controlling disease progression and provides patients with an effective treatment option.

The following is a brief description of relevant information about this drug:

Active Ingredient

Its main active ingredient is idelalisib.

Applicable Population

It is indicated for patients with relapsed chronic lymphocytic leukemia and must be used in combination with rituximab.

Dosage and Administration

The recommended dose is 150 mg orally twice daily, which can be administered continuously until disease progression or unacceptable toxicity occurs. Reference article: Dosage and Administration of Idelalisib

Medication Use in Special Populations

Patients of childbearing potential need to take effective contraceptive measures.

Use in children is not recommended.

Elderly patients need close monitoring for adverse reactions.

Drug Overdose

There is currently no specific antidote. In case of drug overdose, symptomatic and supportive treatment should be given.

Storage Conditions

The drug should be stored at 20–30°C and kept in its original packaging intact.

Pharmacokinetics

The drug is rapidly absorbed after oral administration, is mainly metabolized in the liver, and has a terminal half-life of approximately 8.2 hours.

FDA，2022.02